

- treated with ^{131}I for thyroid cancer. *J Nucl Med* 17:460-464, 1976
14. VARMA VM, BEIERWALTES WH, NOFAL MM, et al: Treatment of thyroid cancer: Death rates after surgery and after surgery followed by sodium iodide I-131. *JAMA* 214: 1437-1442, 1970
 15. NÉMEC J, RÖHLING S, ZAMRAZIL V, et al: Comparison of the distribution of diagnostic and thyroablative I-131 in the evaluation of differentiated thyroid cancers. *J Nucl Med* 20:92-97, 1979
 16. PROSNITZ LR, KAPP DS, WEISSBERG JB: Radiotherapy (First of two parts). *N Engl J Med* 309:771-777, 1983
 17. PROSNITZ LR, KAPP DS, WEISSBERG JB: Radiotherapy (Second of two parts). *N Engl J Med* 309:834-840, 1983
 18. RAWSON RW, RALL JE, PEACOCK W: Limitation and indications in treatment of cancer of thyroid with radioactive iodine. *J Clin Endocrinol* 11:1128-1142, 1951
 19. HENK JM, HIRTSMAN S, GEAN CM: Whole body scanning and ^{131}I therapy in the management of thyroid carcinoma. *Br J Radiol* 45:369-376, 1972

The Education and Research Foundation of the Society of Nuclear Medicine Fellowship/Pilot Research Grant

The Education and Research Foundation of the Society of Nuclear Medicine welcomes applications for Student Fellowships and Pilot Research grants. These awards are made possible through donations from SNM members as well as from various commercial firms whose products are used in the practice of Nuclear Medicine. Applications received prior to December 15 of any year will be evaluated by the ERF Board on a competitive basis. Awards will be announced on or about February 15 of the following year.

STUDENT FELLOWSHIP GRANTS

These awards are designed to stimulate interest among students in the United States and Canada in the field of Nuclear Medicine. The awards are intended to provide an opportunity to spend elective quarters and/or summers in active departments working and associating with experts in the field. Maximum grant: \$1,500. Letters of application should be submitted in duplicate and should contain the following: applicant's name, address, birth date, period for which support is requested, name and institution of sponsor, previous education, previous research, and brief summary of the proposed project, including an appropriate bibliography. Application forms should be requested from the office of the E&R Foundation. Additional applications may be submitted prior to May 1, 1985.

PILOT RESEARCH GRANTS

The goal of this research support is to provide money to young scientists working in Nuclear Medicine who desire support for a research project. Priority will be given to those proposals that are of a pilot nature in either clinical or basic research. The grants are not intended to support salaries, purchase major equipment, or for travel, but are designed to provide essential materials so that innovative ideas can be quickly tested. Maximum grant:\$3,000. Additional applications may be submitted prior to May 1, 1985.

SPECIAL ANNOUNCEMENT: FIFTH TETALMAN MEMORIAL AWARD

A fund has been established in the ERF by friends of Marc Tetelman, M.D., who was a tragic homicide victim while attending the SNM meeting in Atlanta in June 1979. This fund will permit an award of \$3,000 to be made in June, 1985 to a young investigator (35 years of age or younger) who is pursuing a career in Nuclear Medicine. This award is to be repeated annually. It is possible that additional contributions to our fund will permit the stipend to be increased in future years. Applicants should submit prior to March 1, 1985 a curriculum vitae together with data supporting current research efforts.

All letters and applications should be addressed to:

Walter Wolf, Ph.D.
President, E&R Foundation
c/o Society of Nuclear Medicine
475 Park Avenue South
New York, NY 10016

Erratum

In the article entitled "Patterns of Skeletal Scintigraphy and Their Relationship to Plasma and Urinary Levels in Systematic Mastocytosis," Vol. 25, August 1984, pp. 859-864 a line of type was dropped due to a printer's error. The first line, first full paragraph in the second column should read: Laboratory tests of bone disease fail to demonstrate skeletal disease in systematic mastocytosis.